Gemcitabine (GFF) in Patients With Pancreatic Cancer

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CONKO-Studiengruppe
• Collaborator: Eli Lilly and Company
• Treatments: Folic Acid; Gemcitabine; Leucovorin; Levoleucovorin

Criteria

Inclusion Criteria:

• histological proved pancreatic cancer

• inoperable disease

• informed consent

• adequate bone marrow reserve

Exclusion Criteria:

• under 18 years

• brain metastasis

• lactating woman

• life expectancy under 3 months